联系客服

002437 深市 誉衡药业


首页 公告 誉衡药业:2021年度财务决算报告

誉衡药业:2021年度财务决算报告

公告日期:2022-04-26

誉衡药业:2021年度财务决算报告 PDF查看PDF原文

证券代码:002437          证券简称:誉衡药业          公告编号:2022-020
                哈尔滨誉衡药业股份有限公司

                  2021 年度财务决算报告

    哈尔滨誉衡药业股份有限公司(以下简称“公司”)2021 年 12 月 31 日母公
司及合并的资产负债表、2021 年度母公司及合并的利润表、2021 年度母公司及合并的现金流量表、2021 年度母公司及合并的所有者权益变动表及相关报表附注已经上会会计师事务所(特殊普通合伙)审计,并出具了标准无保留意见的审计报告。

    一、2021 年度经营成果

    报告期内,公司实现营业收入 31.45 亿元,较同期上升 2.96%;实现归属于
上市公司股东净利润 4,504.20 万元,同比下降 88.74%。主要会计数据和财务指标如下:

                            2021 年        2020 年      本年比上年增减      2019 年

营业收入(元)            3,145,311,703.84 3,054,949,266.91              2.96% 5,053,859,894.87

归属于上市公司股东的净利

润(元)                    45,042,024.98  400,049,122.39            -88.74% -2,661,773,278.26

归属于上市公司股东的扣除

非经常性损益的净利润(元)  -26,373,724.22  -305,146,631.09              91.36% -2,596,306,299.91

经营活动产生的现金流量净

额(元)                  274,181,021.44    12,763,852.33          2,048.11%  610,365,817.76

基本每股收益(元/股)              0.0205          0.1820            -88.74%        -1.2109

稀释每股收益(元/股)              0.0205          0.1820            -88.74%        -1.2109

加权平均净资产收益率              2.41%        23.94%            -21.53%        -91.21%

                            2021 年末      2020 年末    本年末比上年末增减    2019 年末

总资产(元)              4,695,143,655.89 4,516,310,694.76              3.96% 6,407,579,736.43

归属于上市公司股东的净资

产(元)                  1,894,213,426.48 1,846,228,322.01              2.60% 1,521,364,082.87

    二、主营业务分析

    1、收入与成本

    ⑴ 营业收入构成

                                                                                  单位:元

                          2021 年                        2020 年              同比增减

                    金额      占营业收入比重      金额      占营业收入比重

营业收入合计    3,145,311,703.84          100% 3,054,949,266.91          100%          2.96%

分行业


中药            148,433,044.94          4.72%  279,635,982.83          9.15%        -46.92%

化学药          2,977,427,047.98        94.66% 2,757,668,430.30        90.27%          7.97%

其他              19,451,610.92          0.62%  17,644,853.78          0.58%        10.24%

分产品

心脑血管药物    654,204,474.55        20.80%  828,933,359.15        27.13%        -21.08%

骨科药物        301,418,971.66          9.58%  360,168,437.53        11.79%        -16.31%

营养类药物      1,020,366,461.82        32.44%  692,320,802.31        22.66%        47.38%

抗感染药物      243,641,822.29          7.75%  232,332,301.07          7.61%          4.87%

免疫增强药物      20,294,937.26          0.65%  36,560,807.53          1.20%        -44.49%

抗肿瘤药物      237,895,940.21          7.56%  203,308,615.62          6.66%        17.01%

电解质类药物    186,823,864.48          5.94%  132,228,476.85          4.33%        41.29%

血液系统药物    255,042,425.58          8.11%  246,050,080.98          8.05%          3.65%

抗肝炎药物        43,388,141.77          1.38%  58,672,222.14          1.92%        -26.05%

消化系统药物      39,611,153.84          1.26%  47,519,191.69          1.56%        -16.64%

肾病用药          59,548,571.54          1.89%  67,991,624.50          2.23%        -12.42%

其他              83,074,938.84          2.64%  148,863,347.54          4.87%        -44.19%

分地区

国内            3,140,428,811.73        99.84% 3,049,448,729.60        99.82%          2.98%

国外              4,882,892.11          0.16%    5,500,537.31          0.18%        -11.23%

分销售模式

经销模式        2,901,323,109.28        92.24% 2,745,672,858.23        89.88%          5.67%

其他销售模式    243,988,594.56          7.76%  309,276,408.68        10.12%        -21.11%

    ⑵ 营业成本构成

    ① 行业分类

                                                                                  单位:元

                                  2021 年                  2020 年

  行业分类      项目        金额    占营业成本比    金额    占营业成本比  同比增减
                                            重                        重

中药        主营业务成本  40,294,091.70      4.86% 44,128,868.55      5.56%      -8.69%

化学药      主营业务成本 776,179,693.61      93.55% 736,551,402.74      92.88%      5.38%

其他        其他业务成本  13,225,285.57      1.59% 12,319,951.76      1.56%      7.35%

    ② 产品分类

                                                                                  单位:元

                                  2021 年                  2020 年

  产品分类      项目        金额    占营业成本比    金额    占营业成本比  同比增减
                                            重                        重

心脑血管药物 主营业务成本 254,830,413.61      30.71% 251,460,148.46      31.71%      1.34%

骨科药物    主营业务成本  39,686,437.32      4.78% 49,497,920.00      6.24%      -19.82%

营养类药物  主营业务成本  30,934,430.75      3.73% 22,355,278.25      2.82%      38.38%

抗感染药物  主营业务成本  90,920,599.47      10.96% 70,826,392.22      8.93%      28.37%

免疫增强药物 主营业务成本  2,137,827.38      0.26%  6,069,688.17      0.77%      -64.78%

抗肿瘤药物  主营业务成本  36,534,051.37      4.40% 24,015,125.46      3.03%      52.13%


电解质类药物 主营业务成本  68,892,425.27      8.30% 45,156,283.58      5.69%      52.56%

血液系统药物 主营业务成本 231,907,485.02      27.95% 215,618,271.47      27.19%      7.55%

抗肝炎药物  主营业务成本  3,562,014.50      0.43%  3,304,523.24      0.42%      7
[点击查看PDF原文]